Want to see HK:2325 full AI Analyst Report?
Top Page
Yunkang Group Limited
(2325)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$0.51
▼(-48.99% Downside)
Action:Reiterated
Date:06/27/26
The score is held back primarily by weak technicals (trading below all key moving averages with negative MACD) and expensive valuation (very high P/E). Financial performance is mixed: strong cash generation and improved operating results in 2025 help, but multi-year revenue contraction and volatile profitability limit confidence.
Positive Factors
Strong Cash Generation
Strong operating and free cash flow provide internal funding for operations, investment, and balance-sheet needs without relying as heavily on external capital. The improved 2023–2025 cash profile is a durable financial strength, although its relationship with reported profit warrants monitoring.
Negative Factors
Persistent Revenue Contraction
Three consecutive years of declining revenue indicate a materially smaller business base and weakening commercial momentum rather than a single-period setback. Continued contraction can reduce operating leverage, constrain reinvestment, and make it harder for the company to convert improved margins into durable earnings growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Cash Generation
Strong operating and free cash flow provide internal funding for operations, investment, and balance-sheet needs without relying as heavily on external capital. The improved 2023–2025 cash profile is a durable financial strength, although its relationship with reported profit warrants monitoring.
Read all positive factors
Yunkang Group Limited (2325) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$316.84M
Dividend Yield0.2%
Average Volume (3M)167.41K
Price to Earnings (P/E)4.4
Beta (1Y)0.14
Revenue Growth-15.53%
EPS GrowthN/A
CountryHK
Employees1,064
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.10
Shares Outstanding621,250,500
10 Day Avg. Volume342,900
30 Day Avg. Volume167,408
Financial Highlights & Ratios
PEG Ratio-1.77
Price to Book (P/B)0.45
Price to Sales (P/S)0.87
P/FCF Ratio2.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$884.18M
Yunkang Group Limited Business Overview & Revenue Model
Company Description
Yunkang Group Limited, established in 2008 and headquartered in Guangzhou, People's Republic of China, operates as a comprehensive provider of medical operational services. The company offers a wide range of diagnostic testing solutions to medical...
Yunkang Group Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
53
Neutral
Cash Flow
69
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 540.93M | 601.39M | 711.88M | 891.50M | 3.76B | 1.70B |
| Gross Profit | 154.65M | 182.82M | 211.07M | 325.79M | 1.47B | 1.07B |
| EBITDA | 113.82M | 122.69M | -668.52M | 25.07M | 569.53M | 496.15M |
| Net Income | 60.70M | 2.92M | -791.68M | -102.26M | 377.31M | 380.93M |
Balance Sheet | ||||||
| Total Assets | 2.69B | 2.74B | 3.23B | 4.53B | 5.51B | 3.00B |
| Cash, Cash Equivalents and Short-Term Investments | 1.64B | 1.77B | 1.73B | 1.87B | 1.43B | 800.70M |
| Total Debt | 688.17M | 692.60M | 1.07B | 1.39B | 786.12M | 362.02M |
| Total Liabilities | 1.53B | 1.57B | 2.08B | 2.41B | 2.66B | 1.23B |
| Stockholders Equity | 1.16B | 1.16B | 1.14B | 2.33B | 2.84B | 1.45B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 246.23M | 228.38M | 271.63M | -239.05M | 141.06M |
| Operating Cash Flow | 0.00 | 301.61M | 258.84M | 333.84M | 130.33M | 413.26M |
| Investing Cash Flow | 0.00 | 313.56M | 354.02M | -153.94M | -1.25B | 310.72M |
| Financing Cash Flow | 0.00 | -414.36M | -535.63M | 276.48M | 1.10B | -215.32M |
Yunkang Group Limited Technical Analysis
Negative
0.99
Price Trends
0.62
Negative
0.69
Negative
0.79
Negative
Market Momentum
-0.03
Positive
27.55
Positive
16.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2325, the sentiment is Negative. The current price of 0.99 is above the 20-day moving average (MA) of 0.59, above the 50-day MA of 0.62, and above the 200-day MA of 0.79, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 27.55 is Positive, neither overbought nor oversold. The STOCH value of 16.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2325.
Yunkang Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | HK$469.86M | -145.50 | -0.41% | ― | 3.16% | -101.02% | |
56 Neutral | HK$1.23B | 84.76 | 0.48% | 1.02% | -3.26% | ― | |
53 Neutral | HK$583.79M | 10.64 | 28.00% | ― | 91.32% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$316.84M | 4.40 | 5.25% | 0.20% | -15.53% | ― | |
46 Neutral | HK$515.57M | -1.34 | -25.36% | 1.47% | -8.94% | -140.82% |
* Healthcare Sector Average
HK:2325
Yunkang Group Limited
0.51
-1.00
-66.23%
HK:2138
EC Healthcare
0.46
-0.36
-43.83%
HK:2159
Mediwelcome Healthcare Management & Technology Inc.
1.72
0.26
17.81%
HK:2279
Yonghe Medical Group Co., Ltd.
1.98
-0.50
-20.23%
HK:3869
Hospital Corporation of China Ltd
3.40
-3.39
-49.93%
HK:3886
Town Health International Medical Group Ltd.
0.18
-0.08
-31.13%
Yunkang Group Limited Corporate Events
Yunkang Swings to Profit Despite Revenue Drop on Cost Cuts and Efficiency Gains
Aug 28, 2026
Yunkang Group Limited, a healthcare diagnostics service provider focused on medical institution alliances, diagnostic outsourcing, and non-medical testing services in China, continues to refine its customer mix and product portfolio to strengthen ...
Yunkang Group Sets August Board Meeting to Review Interim Results and Dividend
Aug 18, 2026
Yunkang Group Limited has scheduled a board meeting for August 28, 2026 to approve its interim results for the six months ended June 30, 2026 and to authorize their publication. The directors will also consider the declaration of an interim divide...
Yunkang Shareholders Approve All AGM Resolutions, Renew Capital Mandates
Jun 26, 2026
Yunkang Group Limited reported that all resolutions at its 26 June 2026 annual general meeting were approved by shareholders through a poll, with 585,344,654 shares eligible to vote after the trustee of its restricted share unit scheme abstained i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.